Mogamulizumab-induced granulomatous dermatitis of the scalp: a distinct entity associated with clinical response
J Eur Acad Dermatol Venereol
.
2022 Oct;36(10):e803-e805.
doi: 10.1111/jdv.18284.
Epub 2022 Jun 11.
Authors
A Pacaud
#
1
,
E Criquet
#
2
,
A Durlach
3
,
S Menguy
4
,
M Bagot
5
,
M Ehret
2
,
L Visseaux
2
,
M Beylot-Barry
1
6
,
A Pham-Ledard
#
1
6
,
F Grange
#
2
7
Affiliations
1
Department of Dermatology, Bordeaux University Hospital, Bordeaux, France.
2
Department of Oncodermatology, Reims University Hospital, Reims, France.
3
Department of Pathology, Reims University Hospital, Reims, France.
4
Department of Pathology, Bordeaux University Hospital, Bordeaux, France.
5
Department of Dermatology, Saint-Louis Hospital, Paris, France.
6
Team 5 Translational Research on Oncodermatology and Orphean Skin Diseases, INSERM 1312, Bordeaux University, Bordeaux, France.
7
Department of Dermatology, Valence Hospital, Valence, France.
#
Contributed equally.
PMID:
35648425
DOI:
10.1111/jdv.18284
No abstract available
Publication types
Letter
MeSH terms
Antibodies, Monoclonal, Humanized / adverse effects
Autoimmune Diseases*
Dermatitis* / drug therapy
Dermatitis* / etiology
Humans
Scalp
Substances
Antibodies, Monoclonal, Humanized
mogamulizumab